Abstract:Background: Despite advances in breast carcinoma therapies, drug resistance mechanisms as anti-apoptosis and anti-pyroptosis limit the application of these therapies. This work assesses the immunohistochemical (IHC) expression of Caspase1 and EGFR in breast carcinoma and analyzes their clinicopathological associations as prognostic markers and potential therapeutic targets. Caspase1/EGFR expression patterns are utilized to specify breast carcinoma patients who may benefit from these therapies. Methods: After reviewing the hematoxylin and eosin-stained slides and the routine breast carcinoma IHC stains (estrogen receptors, progesterone receptors, HER2/NEU, Ki-67) by two pathologists and preparation of tissue microarray blocks, anti-Caspase-1 and EGFR IHC staining was performed using Horseradish Peroxidase (HRP) technique. Intensity and percentage-based scoring was applied dividing the 153 included breast carcinomas into Caspase1-negative and positive expression groups; and EGFR low and overexpression groups. Groups were statistically analyzed in relation to age, tumor size, histological and molecular subtype, grade, nodal status, metastasis/recurrence, TNM stage and Ki-67 proliferation index. Kaplan-Meier's analysis was used to compare disease-free survival (DFS) and overall survival (OS). Combined patterns based on Caspase1 and EGFR expression status were created to stratify patients into prognostic groups. Results: Caspase1 was positive in 54.2% of breast carcinomas and its positivity was significantly associated with smaller tumor size, absence of metastasis/recurrence, luminal A and B molecular subtypes and longer OS (p<0.05). EGFR overexpression was detected in 32.7% of carcinomas and was significantly associated with larger tumor size, TNBLBC and a shorter OS (p<0.05). Caspase1-negative/EGFR-overexpression pattern comprised 14.4% of carcinomas and had the worst prognostic associations including larger tumor size, metastasis/recurrence, TNBLBC subtype and shortest OS (p=0.002, 0.002, 0.004 and ≤0.001 respectively). Conclusions: Combined Caspase1/EGFR IHC expression may provide a tool for selection of patients who benefit from combined EGFR-inhibitors with miR-155-5p down-regulators or photodynamic therapy via induction of apoptosis/pyroptosis in EGFR-overexpression carcinomas through enhanced Caspase1 signaling.

Impact of immunohistochemical expression of kinesin family member 18A (Kif18A) and β-catenin in infiltrating breast carcinoma of no special type

KIF18B is a Prognostic Biomarker and Correlates with Immune Infiltrates in Pan-Cancer

Silencing of KIF18B Restricts Proliferation and Invasion and Enhances the Chemosensitivity of Breast Cancer Via Modulating Akt/GSK‐3β/β‐catenin Pathway

Association of different patterns of expression of beta-catenin and cyclin D1 with pathogenesis of breast carcinoma

Expression of KIF2A, NDC80, CDK1, and CCNB1 in breast cancer patients: Their interaction and linkage with tumor features and prognosis

Immunohistochemical Expression of Fn14 and Cath-D as Prognostic Biological Markers and Compare with Histological Reaction in Invasive Human Breast Cancer

Identification of Novel Molecular Therapeutic Targets and Their Potential Prognostic Biomarkers Among Kinesin Superfamily of Proteins in Pancreatic Ductal Adenocarcinoma

KIF18B: an important role in signaling pathways and a potential resistant target in tumor development

KIF18A promotes cervical squamous cell carcinoma progression by activating the PI3K/AKT pathway through upregulation of CENPE

Elevated Expression of KIF 18 A Enhances Cell Proliferation and Predicts Poor Survival in Human Clear Cell Renal Carcinoma

KIF2C is a Novel Prognostic Biomarker and Correlated with Immune Infiltration in Endometrial Cancer.

Immunohistochemical Expression of Caspase1 and Epidermal Growth Factor Receptor in Invasive Breast Carcinoma and Their Biological and Prognostic Associations

Kinesin Family Member-18A (KIF18A) Promotes Cell Proliferation and Metastasis in Hepatocellular Carcinoma

Characterization of KIF20B as a novel prognostic biomarker and therapeutic target for breast cancer

Prognostic Value and Immunological Role of KIFC1 in Hepatocellular Carcinoma

Overexpression of kinesin superfamily members as prognostic biomarkers of breast cancer

Kif18b Promotes Tumor Progression In Osteosarcoma By Activating Beta-Catenin

Β-Catenin Expression:The Role in Carcinogenesis and Development of Human Breast Cancer

Kinesin Family Member 23 Exerts a Protumor Function in Breast Cancer Via Stimulation of the Wnt/β-catenin Pathway

Identification of KIFC1 as an independent prognostic marker in renal clear cell carcinoma correlates with tumor proliferation and immune infiltration

KIF18A knockdown reduces proliferation, migration, invasion and enhances radiosensitivity of esophageal cancer